Development, expression, and murine testing of a multistage Plasmodium falciparum malaria vaccine candidate

Vaccine

Volumn 18, Issue 25, 2000, Pages 2902-2914

  Shi, Ya Ping ^a   Das, Parimal ^b   Holloway, Brian ^c   Udhayakumar, Venkatachalam ^a   Tongren, Jon Eric ^a   Candal, Francisco ^c   Biswas, Sukla ^a,d   Ahmad, Raies ^b   Hasnain, Seyed E ^b,e   Lal, Altaf A ^a  

^a Div Parasitic Dis Natl Ctr I   (United States)

^b NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^c NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^d NATIONAL INSTITUTE OF MALARIA RESEARCH   (India)

^e CENTRE FOR DNA FINGERPRINTING AND DIAGNOSTICS   (India)

Author keywords

Immune response; P. falciparum; Vaccine

Indexed keywords

EPITOPE; GAMMA INTERFERON; MALARIA VACCINE; PARASITE ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; IMMUNOGENICITY; MALARIA CONTROL; MALARIA FALCIPARUM; MOLECULAR CLONING; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION;

EID: 0041470472     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00045-1     Document Type: Article

References (44)

1. World Health Organization. Wkly Epidemiol. Res. 32:1989;241-247.
2. Institute of Medicine. Malaria: obstacles and opportunities. 1989;1-6 National Academy Press, Washington, DC.
3. Hoffman S.L. Malaria Vaccine development: a multi-immune response approach. 1996;1-12 American Society for Microbiology Press, Washington, DC.
4. Patarroyo M.E., Remero P., Torres M.L., Clavijo P., Moreno A., Martinez A. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature. 328:1987;629-632.
5. Bathurst I.C., Gibson H.L., Kansopon J., Hahm B.K., Green K.M., Chang S.P., Hui G.S., Siddiqui W.A., Inselburg J., Millet P. An experimental vaccine cocktail for Plasmodium falciparum malaria. Vaccine. 11:1993;449-456.
6. Tine J.A., Lanar D.E., Smith D.M., Wellde B.T., Schultheiss P., Ware L.A., Kauffman E.B., Wirtz R.A., De Taisne C., Hui G.S., Chang S.P., Church P., Hollingdale M.R., Kaslow D.C., Hoffman S., Guito K.P., Ballou W.R., Sadoff J.C., Paoletti E. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect. Immun. 64:1996;3833-3844.
7. Gilbert S.C., Plebanski M., Harris S.J., Allsopp C.E., Thomas R., Layton G.T., Hill A.V. A protein particle vaccine containing multiple malaria epitopes. Nat. Biotechnol. 15:1997;1280-1284.
8. Wosnick M.S., Barnett R.W., Vicentini A.M., Erfle H., Elliott R., Sumner-Smith M., Mantei N., Davies R.W. Rapid construction of large synthetic genes: total chemical synthesis of two different version of the bovine prochymosin gene. Gene. 60:1987;115-127.
9. Habuka N., Murakami Y., Noma M., Kudo T., Horikoshi K. Amino acid sequence of Mirabilis antiviral protein, total sythesis of its gene and expression in Escherichia coli. J. Biol. Chem. 264:1989;6629-6637.
10. Barnett R., Erfle H. Rapid generation of DNA fragments by PCR amplification of crude, synthetic oligonucleotides. Nucleic Acids Res. 18:1990;3094-3098.
11. Dillon F.J., Rosen C.A. A rapid method for the construction of synthetic genes using the polymerase chain reaction. Biotechniques. 9:1990;298-300.
12. Horton R.M., Hunt H.D., Ho S.N., Pullen J.K., Pease L.R. Engineering hybrid genes without the use of restriction enzymes: genesplicing by overlap extension. Gene. 77:1989;61-68.
13. Shi Y.P., Hasnain S.E., Sacci J.B., Holloway B.P., Fujioka H., Kumar N., Wohlhueter R., Hoffman S.L., Collins W.E., Lal A.A. Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine. Proc. Natl. Acad. Sci. USA. 96:1999;1615-1620.
14. Udhayakumar V., Anyona D., Kariuki S., Shi Y.P., Bloland P.B., Branch O.H., Weiss W., Nahlen B.L., Kaslow D.C., Lal A.A. Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1. J. Immun. 154:1995;6022-6030.
15. Lal A.A., Hughes M.A., Oliveira D.A., Nelson C., Bloland P.B., Oloo A.J., Hawley W.E., Hightower A.W., Nahlen B.L., Udhayakumar V. Identification of T-cell determinants in natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in an adult population exposed to malaria. Infect. Immun. 64:1996;1054-1059.
16. Shi Y.P., Udhayakumar V., Alpers M.P., Povoa M.M., Oloo A.J., Ruebush T.K. II, Lal A.A. Natural antibody responses against the non-repeat-sequence-based B-cell epitopes of Plasmodium falciparum circumsporozoite protein. Infect. Immun. 61:1993;2425-2433.
17. UdhayaKumar V., Ongecha J.M., Shi Y.P., Aidoo M., Orago A.S.S., Oloo A.J., Hawley W.A., Nahlen B.L., Hoffman S.L., Weiss W.R., Lal A.A. Cytotoxic T cell reactivity and HLA-B35 binding of the variant Plasmodium falciparum circumsporozoite protein CD8+ CTL epitope in naturally exposed Kenyan adults. Eur. J. Immun. 27:1997;1952-1957.
18. Saul A., Lord R., Jones G.L., Spencer L. Protective immunization with invariant peptides of the Plasmodium falciparum antigen MSA2. J. Immunol. 148:1995;208-211.
19. Sim B.K.L., Carter J.M., Deal C.D., Holland C., Haynes J.D., Gross M. Plasmodium falciparum: further charcterization of functionally active region of the merozoite invasion ligand EBA-175. Exp. Parasitol. 78:1994;259-268.
20. Harnyuttanakorn, Mcbride J.S., Donachie S., Heidrich H.-G., Ridley R.G. Inhibitory monoclonal antibodies recognise epitopes adjacent to a proteolytic cleavage site on the RAP-1 protein of Plasmodium falciparum. Molec. Biochem. Parasitol. 55:1992;177-186.
21. Kumar S., Miller L.H., Quakyi I.A., Keister D.B., Houghten R.A., Maloy W.L., Moss B., Berzofsky J.A., Good M.F. Cytotoxic T cells specific for the circumsporozoite protein of Plasmodium falciparum. Nature. 334:1988;258-260.
22. Sinigaglia F., Guttinger M., Kilgus J., Doran D.M., Matile H., Etlingerr, Trzeciak A., Gillessen D., Pink J.R.L. A malaria T-cell epitopes recognized in association with most mouse and human MHC class II molecules. Nature. 336:1988;778-780.
23. Zavala F., Tam J.P., Hollingdale M.R., Cochrane A.H., Quakyi I., Nussenzweig R.S., Nussenzweig V. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science. 228:1985;1436-1440.
24. Rogers W.O., Malik A., Mellouk S., Nakamura K., Rogers M.D., Szarfman A., Gordon D.M., Nussler A.K., Aikawa M., Hoffman S.L. Characterization of Plasmodium falciparum sporozoite surface protein 2. Proc. Natl. Acad. Sci. USA. 89:1992;9176-9180.
25. Hill A.V.S., Elvin J., Willis A.C., Aidoo M., Allsopp C.E.M., Gotch F.M., Gao X.M., Takiguchi M., Greenwood B.M., Townsend A.R.M., McMichael A.J., Whittle H.C. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature. 360:1992;434-439.
26. Ploton IN, Wizel B, Viscidi R, Kumar N. Mapping of two overlapping linear epitopes in Pfg27 recognized by Plasmodium falciparum transmission-blocking monoclonal antibodies. Vaccine 1995;13:1161-19.
27. Panina-Bordignon P., Tan A., Termijtelen A., Demotz S., Corradin G.P., Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human class II and promiscuous recognition by T cells. Eur. J. Immunol. 19:1989;2237-2242.
28. Tessier D.C., Thomas D.Y., Khouri H.E., Laliberte F., Vernet T. Enhanced secretion from insect cells of a foreign protein fused to honeybee melittin signal peptide. Gene. 98:1991;177-183.
29. Sinha N.D., Biernat J., McManus J., Koster H. Polymer support oligonucleotide synthesis XVIII: use of beta-cyanoethyl-N,N-dialkylamino-/N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product. Nucleic Acids Res. 12:1984;4539-4557.
30. Applied Biosystems User Bulletin #13. In: The Evaluation and Purification of Synthetic Oligonucleotides. Foster City, CA: PE Applied Biosystems, 1987.
31. Sanger F., Nicklen S., Coulson A.R. DNA sequencing with chain-terminating inhibitor. Proc. Natl. Acad. Sci. USA. 74:1977;5463-5467.
32. Chatterjee U., Ahmad R., Venkaiah B., Hasnain S.E. A recombinant-efficient baculovirus vector for simultaneous expression of multiple gene. Gene. 171:1996;209-213.
33. Sridhar P., Hasnain S.E. Differential secretion and glycosylation of recombinant human chorionic gonadotropin (bhCG) synthesized using different promoters in the baculovirus expression vector system. Gene. 131:1993;261-264.
34. Shi Y.P., Sayed U., Qari S.H., Roberts J.M., Udhayakumar V., Oloo A.J., Hawley W.A., Kaslow D.C., Nahlen B.L., Lal A.A. Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1. Infect. Immun. 64:1996;2716-2723.
35. Tsang V.C.W., Hancock K., Wilson M. Enzyme-linked immunoelectrotransfer blot technique (Western blot) for human T-lymphotropic virus type III/lymphadenophy-associated virus (HTLV-III) antibodies. 1986;1-25 CDC, Public Health Service, US Department of Health and Human Services, Atlanta.
36. Holowachuk E.W., Ruhoff M.S. Efficient gene synthesis by Klenow assembly/extension-Pfu polymerase amplification (KAPPA) of overlapping oligonucleotides. PCR methods and applications. 1995;299-302 Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press.
37. Bergseid M., Scott B., Mathor S., Nlelson K., Shoemaker D., Mathur E. A high fidelity thermostable DNA polymerase isolated from Pyrococcus furtasus. Strategies. 4:1991;34-35.
38. Chang S.P., Gibson H.L., Lee-Ng C.T., Barr P.J., Hui G.S. A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. J. Immunol. 149:1992;548-555.
39. Ranjan A., Hasnain S.E. Influence of codon usage and translational initiation codon context in the AcNPV-based expression system: computer analysis using homologous and heterologous genes. Virus Genes. 9:1995;149-153.
40. Ranjan A., Hasnain S.E. Codon usage in the prototype baclovirus-Autographa californica nucler polyhedrosis virus. Indian J. Biochem Biophys. 32:1995;424-428.
41. Thomson S.A., Khanna R., Gardner J., Burrows S.R., Coupar B., Moss D.J., Suhrbier A. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. Proc. Natl. Acad. Sci. USA. 92:1995;5845-5849.
42. Isaruliants M.G., Ruden U., Wahren B. Composition of HIV-1 B-epitopes and heterologous T-cell epitopes. II. Combined analysis of immunogenicity of composite peptides in rabbits. Biokhimiia. 61:1996;1230-1240.
43. Nelson C., Viavsky I., Viner N.J., Gross M.L., Unanue E.R. Amino-terminal trimming of peptides for presentation on major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA. 94:1997;628-633.
44. Troye-Blomberg M., Perlman P. Malaria immunity: an overview with emphasis on T cell function. Good M.F., Saul A.J. Molecular immunologic considerations in vaccine development. 1994;1-46 CRC Press, Boca Raton, FL.